Hospital
Dignity Health
Dignity Health was paid $45.52M by Medicaid between Jan 2018 and Dec 2024, across 234 billing codes. Its largest line is 0450, Emergency room services — 15% of everything it billed.
33Billing provider infoDIGNITY HEALTH
SACRAMENTO, CA 95819
SACRAMENTO, CA 95819
33aNPI1487694857assigned 06/07/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$45.52M
24GClaims736,426
24DCodes billed234
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in California
Rank by total paid#5 of 22
Median peer was paid$308K
This provider vs. median148×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 133,413 | $7.01M | |
| 2019 | 132,017 | $7.49M | |
| 2020 | 91,086 | $5.65M | |
| 2021 | 99,771 | $6.37M | |
| 2022 | 97,087 | $6.57M | |
| 2023 | 106,319 | $7.09M | |
| 2024incomplete | 76,733 | $5.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 15% | 24,946 | 22,226 | $6.72M |
| A9150 | Non-prescription drugs | 14% | 25,291 | 10,934 | $6.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 22,415 | 20,895 | $4.49M |
| 36415 | Collection of venous blood by venipuncture | 9.7% | 34,769 | 29,923 | $4.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 24,005 | 22,404 | $3.47M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 11,403 | 10,683 | $3.40M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 5.7% | 10,162 | 5,710 | $2.61M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 6,135 | 5,843 | $1.20M |
| 80053 | Comprehensive metabolic panel | 2.0% | 38,565 | 35,661 | $898K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 3,703 | 3,626 | $645K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 5,060 | 4,911 | $562K |
| 99499 | 1.0% | 1,546 | 959 | $471K |
222 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,578 | $445K |
| J3490 | Unclassified drugs | <1% | 42,088 | $350K |
| 0270 | <1% | 24,331 | $336K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,930 | $307K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,948 | $304K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,938 | $303K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,107 | $302K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,576 | $291K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,891 | $276K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,604 | $256K |
| 0360 | <1% | 1,631 | $250K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,790 | $239K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,665 | $216K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,886 | $215K |
| G0378 | Hospital observation service, per hour | <1% | 220 | $214K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,522 | $213K |
| 99199 | Unlisted special service, procedure or report | <1% | 1,757 | $210K |
| 97750 | <1% | 8,218 | $202K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 462 | $199K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,463 | $198K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 612 | $189K |
| 0250 | <1% | 3,181 | $187K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,544 | $172K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,909 | $165K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 947 | $164K |
| 84484 | <1% | 13,800 | $161K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,368 | $158K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,116 | $141K |
| Z7502 | <1% | 3,684 | $137K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,229 | $135K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 189 | $122K |
| 99201 | <1% | 383 | $120K | |
| 0710 | <1% | 1,329 | $117K | |
| 97139 | <1% | 15,135 | $102K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 362 | $98K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 679 | $96K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,375 | $88K |
| 81001 | <1% | 14,513 | $85K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,846 | $83K |
| 82962 | <1% | 5,311 | $79K | |
| 83880 | <1% | 4,984 | $77K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,257 | $76K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,895 | $71K |
| 83690 | <1% | 12,502 | $67K | |
| 93971 | <1% | 1,200 | $65K | |
| Z9725 | <1% | 2,050 | $62K | |
| 0760 | <1% | 1,680 | $60K | |
| 73562 | <1% | 1,152 | $58K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,362 | $55K |
| 87040 | <1% | 4,108 | $52K | |
| 73610 | <1% | 1,016 | $52K | |
| 73630 | <1% | 1,305 | $51K | |
| 84703 | <1% | 7,042 | $49K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,107 | $49K |
| 81003 | <1% | 7,236 | $48K | |
| 0160 | <1% | 86 | $47K | |
| 73030 | <1% | 861 | $45K | |
| 83605 | <1% | 5,714 | $44K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,978 | $43K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,774 | $43K |
| 87081 | <1% | 1,762 | $42K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,199 | $41K |
| 59025 | Fetal non-stress test | <1% | 3,088 | $41K |
| A9270 | Non-covered item or service | <1% | 7,338 | $40K |
| 81025 | <1% | 4,046 | $37K | |
| 85027 | <1% | 9,146 | $36K | |
| 73130 | <1% | 666 | $35K | |
| 87077 | <1% | 2,166 | $35K | |
| 76830 | Ultrasound, transvaginal | <1% | 943 | $33K |
| 99153 | Mod sedat endo service >5yrs | <1% | 634 | $33K |
| 76801 | <1% | 901 | $30K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,952 | $29K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 343 | $28K |
| 0324 | <1% | 188 | $27K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,171 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 809 | $26K |
| 96376 | <1% | 615 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,214 | $25K |
| 84702 | <1% | 2,440 | $24K | |
| 83735 | <1% | 3,936 | $21K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 50 | $20K |
| 85610 | <1% | 5,783 | $20K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,258 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,788 | $19K |
| 73110 | <1% | 346 | $19K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 650 | $19K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 742 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 844 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,362 | $18K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,018 | $17K |
| 82803 | <1% | 1,037 | $17K | |
| 94060 | <1% | 1,216 | $17K | |
| 99152 | <1% | 220 | $17K | |
| T5999 | Supply, not otherwise specified | <1% | 150 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,060 | $16K |
| 87631 | <1% | 412 | $16K | |
| 94729 | <1% | 1,380 | $15K | |
| 85730 | <1% | 2,707 | $15K | |
| 70486 | <1% | 68 | $15K | |
| 10060 | <1% | 155 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,605 | $14K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,001 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,479 | $14K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 156 | $14K |
| 86885 | <1% | 1,555 | $14K | |
| 0720 | <1% | 272 | $13K | |
| 85379 | <1% | 1,984 | $13K | |
| 94726 | <1% | 1,211 | $13K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $12K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,843 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,429 | $12K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 31 | $11K |
| 80076 | <1% | 1,544 | $11K | |
| 86901 | <1% | 1,973 | $10K | |
| 80061 | Lipid panel | <1% | 775 | $10K |
| 97161 | <1% | 311 | $10K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 760 | $9K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 385 | $8K |
| 99070 | <1% | 859 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,205 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 572 | $8K |
| 93798 | <1% | 953 | $7K | |
| 85007 | <1% | 2,384 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,590 | $7K |
| 87186 | <1% | 1,765 | $7K | |
| 0949 | <1% | 134 | $7K | |
| Z7610 | <1% | 1,034 | $7K | |
| 84145 | <1% | 691 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,250 | $6K |
| 86141 | <1% | 1,128 | $6K | |
| 86900 | <1% | 2,165 | $6K | |
| 86923 | <1% | 139 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 310 | $6K |
| 0301 | <1% | 59 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 261 | $6K |
| 90715 | <1% | 511 | $6K | |
| 50590 | <1% | 13 | $6K | |
| 36430 | <1% | 79 | $5K | |
| 72131 | <1% | 50 | $5K | |
| 86880 | <1% | 575 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 555 | $5K |
| C1769 | Guide wire | <1% | 94 | $5K |
| V2632 | Posterior chamber intraocular lens | <1% | 84 | $5K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 69 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,804 | $4K |
| 0272 | <1% | 230 | $4K | |
| 93017 | <1% | 70 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 414 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 631 | $3K |
| 73590 | <1% | 28 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $3K |
| 72100 | <1% | 108 | $3K | |
| 82010 | <1% | 237 | $3K | |
| 94644 | <1% | 241 | $3K | |
| 73502 | <1% | 72 | $3K | |
| 73090 | <1% | 51 | $3K | |
| 29125 | <1% | 156 | $3K | |
| 0370 | <1% | 200 | $3K | |
| 0761 | <1% | 84 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,109 | $3K |
| 73080 | <1% | 43 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 671 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,266 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 867 | $2K |
| 74018 | <1% | 89 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 55 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 465 | $2K |
| 76770 | <1% | 54 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 180 | $2K |
| 12001 | <1% | 30 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 232 | $2K |
| 85651 | <1% | 307 | $2K | |
| 88342 | <1% | 152 | $2K | |
| 87147 | <1% | 129 | $1K | |
| 74174 | <1% | 13 | $1K | |
| 36600 | <1% | 155 | $1K | |
| 87275 | <1% | 75 | $1K | |
| 93970 | <1% | 29 | $1K | |
| 88341 | <1% | 27 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 16 | $1K |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 411 | $1K |
| 82550 | <1% | 187 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 114 | $980.07 |
| 93000 | <1% | 13 | $916.19 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 73 | $909.69 |
| 0002A | <1% | 26 | $904.54 | |
| 96367 | <1% | 47 | $898.60 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 37 | $878.76 |
| 71020 | <1% | 23 | $865.39 | |
| 84132 | <1% | 175 | $715.30 | |
| 0001A | <1% | 37 | $664.44 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 15 | $620.90 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 82 | $516.10 |
| 88304 | <1% | 72 | $463.78 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 76 | $446.64 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 78 | $393.74 |
| 87428 | <1% | 31 | $363.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 30 | $359.01 |
| 87276 | <1% | 76 | $320.16 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $319.55 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 64 | $318.16 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 839 | $306.91 |
| 94618 | <1% | 50 | $228.40 | |
| 88720 | <1% | 86 | $181.90 | |
| C9399 | Unclassified drugs or biologicals | <1% | 130 | $142.54 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 27 | $141.11 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 58 | $93.15 |
| 82553 | <1% | 17 | $91.60 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 73 | $89.15 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 62 | $53.54 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 39 | $49.97 |
| 86308 | <1% | 13 | $34.18 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 1,112 | $31.34 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 26 | $27.83 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 307 | $23.49 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 65 | $17.93 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 96 | $11.22 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 163 | $5.61 |
| 91300 | <1% | 16 | $0.05 | |
| S9484 | Crisis intervention mental health services, per hour | 0% | 95 | $0.00 |
| 82140 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.